Edition:
United States

Allergan plc (AGN.N)

AGN.N on New York Stock Exchange

159.31USD
21 Feb 2018
Change (% chg)

$-1.28 (-0.80%)
Prev Close
$160.59
Open
$160.25
Day's High
$162.02
Day's Low
$159.23
Volume
605,616
Avg. Vol
707,180
52-wk High
$256.78
52-wk Low
$156.00

Chart for

About

Allergan plc is a specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of brand name pharmaceutical products, medical aesthetics, biosimilar and over-the-counter pharmaceutical products. The Company operates through three segments: US Specialized Therapeutics, US... (more)

Overall

Beta: 1.26
Market Cap(Mil.): $52,983.81
Shares Outstanding(Mil.): 332.58
Dividend: 0.72
Yield (%): 1.81

Financials

  Industry Sector
P/E (TTM): -- 32.23 16.73
EPS (TTM): -- -- --
ROI: -- 14.02 35.60
ROE: -- 15.49 17.23

BRIEF-Molecular Partners' Partner Allergan Exercises Third Option For Darpin Product Candidate In Ophthalmology

* MOLECULAR PARTNERS' PARTNER ALLERGAN EXERCISES THIRD OPTION FOR DARPIN PRODUCT CANDIDATE IN OPHTHALMOLOGY Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Feb 19 2018

BRIEF-Allergan Files For Potential Mixed Shelf Offering

* ALLERGAN PLC FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING Source text: (http://bit.ly/2EvYOO0) Further company coverage:

Feb 16 2018

Shares of Apricus tank after FDA declines to OK erectile dysfunction cream

The U.S. Food and Drug Administration on Friday declined to approve Apricus Biosciences Inc's Vitaros, a cream to treat erectile dysfunction, for the second time in a decade, sending the company's shares down more than 70 percent before the opening bell.

Feb 16 2018

UPDATE 2-Shares of Apricus tank after FDA declines to OK erectile dysfunction cream

* Co set to lose 76 pct of market value (Adds background on drug, analyst comment, updates share price)

Feb 16 2018

BRIEF-Appaloosa Dissolves Share Stake In GM & Whirlpool, Ups Stake In Allergan

* APPALOOSA LP DISSOLVES SHARE STAKE IN GENERAL MOTORS CO - SEC FILING

Feb 14 2018

BRIEF-Allergan Declares Q1 2018 Cash Dividend Of $0.72 Per Share

* ALLERGAN DECLARES FIRST QUARTER 2018 CASH DIVIDEND OF $0.72 PER ORDINARY SHARE AND PROVIDES ANNUAL GENERAL MEETING OF SHAREHOLDERS UPDATES Source text for Eikon: Further company coverage:

Feb 09 2018

Allergan's profit beats; migraine drug succeeds in key study

Allergan Plc on Tuesday reported better-than-expected quarterly profit on robust demand for Botox, boosted its earnings forecast and announced positive data on one of the two migraine treatments it is developing.

Feb 06 2018

UPDATE 3-Allergan's profit beats; migraine drug succeeds in key study

Feb 6 Allergan Plc on Tuesday reported better-than-expected quarterly profit on robust demand for Botox, boosted its earnings forecast and announced positive data on one of the two migraine treatments it is developing.

Feb 06 2018

BRIEF-Allergan Reports Q4 Non-GAAP Earnings Per Share $4.86

* ALLERGAN REPORTS SOLID FINISH TO 2017 WITH 12% INCREASE IN FOURTH QUARTER GAAP NET REVENUES TO $4.3 BILLION

Feb 06 2018

Allergan posts quarterly profit; migraine treatment succeeds key study

Feb 6 Allergan Plc posted a quarterly profit, compared with a year-ago loss, due to recent changes in the U.S. tax laws, and the botox maker said its migraine treatment met the main goals in a late-stage study.

Feb 06 2018

Earnings vs. Estimates